|
US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
EP0154316B1
(en)
|
1984-03-06 |
1989-09-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified lymphokine and production thereof
|
|
US4596556A
(en)
|
1985-03-25 |
1986-06-24 |
Bioject, Inc. |
Hypodermic injection apparatus
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
US5374548A
(en)
|
1986-05-02 |
1994-12-20 |
Genentech, Inc. |
Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
|
|
MX9203291A
(es)
|
1985-06-26 |
1992-08-01 |
Liposome Co Inc |
Metodo para acoplamiento de liposomas.
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4881175A
(en)
|
1986-09-02 |
1989-11-14 |
Genex Corporation |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5013653A
(en)
|
1987-03-20 |
1991-05-07 |
Creative Biomolecules, Inc. |
Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
AU612370B2
(en)
|
1987-05-21 |
1991-07-11 |
Micromet Ag |
Targeted multifunctional proteins
|
|
US4941880A
(en)
|
1987-06-19 |
1990-07-17 |
Bioject, Inc. |
Pre-filled ampule and non-invasive hypodermic injection device assembly
|
|
US4790824A
(en)
|
1987-06-19 |
1988-12-13 |
Bioject, Inc. |
Non-invasive hypodermic injection device
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
US5677425A
(en)
|
1987-09-04 |
1997-10-14 |
Celltech Therapeutics Limited |
Recombinant antibody
|
|
GB8809129D0
(en)
|
1988-04-18 |
1988-05-18 |
Celltech Ltd |
Recombinant dna methods vectors and host cells
|
|
US5476996A
(en)
|
1988-06-14 |
1995-12-19 |
Lidak Pharmaceuticals |
Human immune system in non-human animal
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
JP2989002B2
(ja)
|
1988-12-22 |
1999-12-13 |
キリン―アムジエン・インコーポレーテツド |
化学修飾顆粒球コロニー刺激因子
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5312335A
(en)
|
1989-11-09 |
1994-05-17 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
US5064413A
(en)
|
1989-11-09 |
1991-11-12 |
Bioject, Inc. |
Needleless hypodermic injection device
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
EP0746609A4
(en)
|
1991-12-17 |
1997-12-17 |
Genpharm Int |
NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
WO1993022332A2
(en)
|
1992-04-24 |
1993-11-11 |
Board Of Regents, The University Of Texas System |
Recombinant production of immunoglobulin-like domains in prokaryotic cells
|
|
US5383851A
(en)
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
CA2156924A1
(en)
|
1993-12-27 |
1995-07-06 |
Ton That Hai |
Water soluble non-immunogenic polyamide cross-linking agents
|
|
US6066322A
(en)
|
1995-03-03 |
2000-05-23 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of immune disorders
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US6410690B1
(en)
|
1995-06-07 |
2002-06-25 |
Medarex, Inc. |
Therapeutic compounds comprised of anti-Fc receptor antibodies
|
|
US5811097A
(en)
|
1995-07-25 |
1998-09-22 |
The Regents Of The University Of California |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
AU728657B2
(en)
|
1996-03-18 |
2001-01-18 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
JP2001523958A
(ja)
|
1997-03-21 |
2001-11-27 |
ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド |
免疫療法のｃｔｌａ−４結合ペプチド
|
|
DE69833755T2
(de)
|
1997-05-21 |
2006-12-28 |
Biovation Ltd. |
Verfahren zur herstellung von nicht-immunogenen proteinen
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2434961T5
(es)
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
|
DK2112166T3
(en)
|
1998-12-23 |
2019-02-04 |
Pfizer |
Human monoclonal antibodies to CTLA-4
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
EP1176195B1
(en)
|
1999-04-09 |
2013-05-22 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
EP1074563A1
(en)
|
1999-08-02 |
2001-02-07 |
F. Hoffmann-La Roche Ag |
Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
|
|
CA2383424C
(en)
|
1999-08-23 |
2011-02-15 |
Gordon Freeman |
Novel b7-4 molecules and uses therefor
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
EP3225632B1
(en)
|
1999-11-30 |
2020-05-06 |
Mayo Foundation for Medical Education and Research |
Antibodies binding to b7-h1, a novel immunoregulatory molecule
|
|
DK1252192T3
(da)
|
2000-02-11 |
2006-11-20 |
Merck Patent Gmbh |
Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
|
|
US6725230B2
(en)
|
2000-07-18 |
2004-04-20 |
Aegis Analytical Corporation |
System, method and computer program for assembling process data of multi-database origins using a hierarchical display
|
|
JP3523245B1
(ja)
|
2000-11-30 |
2004-04-26 |
メダレックス，インコーポレーテッド |
ヒト抗体作製用トランスジェニック染色体導入齧歯動物
|
|
WO2002092780A2
(en)
|
2001-05-17 |
2002-11-21 |
Diversa Corporation |
Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
|
|
US7129261B2
(en)
|
2001-05-31 |
2006-10-31 |
Medarex, Inc. |
Cytotoxic agents
|
|
US8709412B2
(en)
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
NZ530451A
(en)
|
2001-06-29 |
2008-04-30 |
Univ Leland Stanford Junior |
TIM gene sequences and their use in immunological disorders and cancer
|
|
US7838220B2
(en)
|
2001-06-29 |
2010-11-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
T cell regulatory genes associated with immune disease
|
|
US20030157108A1
(en)
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
|
EP3020413A1
(en)
|
2002-01-30 |
2016-05-18 |
The Brigham and Women's Hospital, Inc. |
Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US20040110226A1
(en)
|
2002-03-01 |
2004-06-10 |
Xencor |
Antibody optimization
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20040014194A1
(en)
|
2002-03-27 |
2004-01-22 |
Schering Corporation |
Beta-secretase crystals and methods for preparing and using the same
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
US7425620B2
(en)
|
2002-08-14 |
2008-09-16 |
Scott Koenig |
FcγRIIB-specific antibodies and methods of use thereof
|
|
WO2004029207A2
(en)
|
2002-09-27 |
2004-04-08 |
Xencor Inc. |
Optimized fc variants and methods for their generation
|
|
DK1562972T3
(da)
|
2002-10-15 |
2010-12-06 |
Facet Biotech Corp |
Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
|
|
EP2368578A1
(en)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
|
CA2514231A1
(en)
|
2003-02-13 |
2004-08-26 |
Pfizer Products Inc. |
Uses of anti-insulin-like growth factor i receptor antibodies
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
MXPA06003686A
(es)
|
2003-10-03 |
2007-03-01 |
Brigham & Womens Hospital |
Ligandos tim-3 y sus metodos.
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
US7276585B2
(en)
|
2004-03-24 |
2007-10-02 |
Xencor, Inc. |
Immunoglobulin variants outside the Fc region
|
|
BRPI0509139A
(pt)
|
2004-03-24 |
2007-08-28 |
Telos Fharmaceuticals Inc |
composição, e, método de estimulação de uma resposta imune em um indivìduo, de tratamento profilático de uma doença, de melhoramento de um sinal ou sintoma associado com uma doença, de alvejamento de um tumor, de inibição do crescimento de tumor, e de detecção de um tumor
|
|
WO2005112919A2
(en)
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
ES2426817T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
EA010654B1
(ru)
|
2004-11-23 |
2008-10-30 |
Пи Ай Пи Ко., Лтд. |
Вмонтированная в стену распределительная коробка водоснабжения
|
|
EP3312196B1
(en)
|
2005-03-23 |
2019-07-17 |
Genmab A/S |
Antibodies against cd38 for treatment of multiple myeloma
|
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
US7714016B2
(en)
|
2005-04-08 |
2010-05-11 |
Medarex, Inc. |
Cytotoxic compounds and conjugates with cleavable substrates
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
RS52711B
(sr)
|
2005-05-10 |
2013-08-30 |
Incyte Corporation |
Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih
|
|
EA019344B1
(ru)
|
2005-07-01 |
2014-03-31 |
МЕДАРЕКС, Эл.Эл.Си. |
Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
|
|
EP1940470B1
(en)
|
2005-09-26 |
2013-04-17 |
Medarex, Inc. |
Antibody-drug conjugates and their use
|
|
EA015324B1
(ru)
|
2005-10-26 |
2011-06-30 |
Медарекс, Инк. |
Способы и соединения для получения аналогов сс-1065
|
|
CA2627190A1
(en)
|
2005-11-10 |
2007-05-24 |
Medarex, Inc. |
Duocarmycin derivatives as novel cytotoxic compounds and conjugates
|
|
EP1971583B1
(en)
|
2005-12-20 |
2015-03-25 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
WO2008036642A2
(en)
|
2006-09-19 |
2008-03-27 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
JP2010510223A
(ja)
|
2006-11-15 |
2010-04-02 |
サ ブリガム アンド ウィメンズ ホスピタル インコーポレーティッド |
Ｔｉｍ−３調節物質の治療的使用
|
|
TWI412367B
(zh)
|
2006-12-28 |
2013-10-21 |
Medarex Llc |
化學鏈接劑與可裂解基質以及其之綴合物
|
|
CA2678514A1
(en)
|
2007-02-21 |
2008-08-28 |
Medarex, Inc. |
Chemical linkers with single amino acids and conjugates thereof
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
DE102007036200A1
(de)
|
2007-08-02 |
2009-02-05 |
Knorr-Bremse Systeme für Nutzfahrzeuge GmbH |
Induktiver Weg- oder Drehwinkelsensor mit zwischen zwei Spulen angeordnetem Abschirmblech
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
CA2703947C
(en)
|
2007-10-26 |
2018-12-04 |
Governing Council Of The University Of Toronto |
Therapeutic and diagnostic methods using tim-3
|
|
CN101918027A
(zh)
|
2007-11-02 |
2010-12-15 |
森托科尔奥索生物科技公司 |
半合成GLP-1肽-Fc融合构造、方法及其用途
|
|
EP2227233B1
(en)
|
2007-11-30 |
2013-02-13 |
Newlink Genetics |
Ido inhibitors
|
|
EP2252319A2
(en)
|
2008-01-29 |
2010-11-24 |
The Brigham and Women's Hospital, Inc. |
Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
|
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
|
US20110044894A1
(en)
|
2008-03-26 |
2011-02-24 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
|
|
JP2011523616A
(ja)
|
2008-05-29 |
2011-08-18 |
サン−ゴバン サントル ドゥ ルシェルシェ エ デトゥードゥ ユーロペン |
チタン酸アルミニウムを含有する多孔質構造体
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
HUE065752T2
(hu)
|
2008-12-09 |
2024-06-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
|
|
JP5569946B2
(ja)
|
2009-01-26 |
2014-08-13 |
国立大学法人 岡山大学 |
免疫抑制剤および自己免疫疾患の予防および治療剤
|
|
WO2010117057A1
(ja)
|
2009-04-10 |
2010-10-14 |
協和発酵キリン株式会社 |
抗tim-3抗体を用いた血液腫瘍治療法
|
|
US20110007023A1
(en)
|
2009-07-09 |
2011-01-13 |
Sony Ericsson Mobile Communications Ab |
Display device, touch screen device comprising the display device, mobile device and method for sensing a force on a display device
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
WO2011056652A1
(en)
|
2009-10-28 |
2011-05-12 |
Newlink Genetics |
Imidazole derivatives as ido inhibitors
|
|
PT2504364T
(pt)
|
2009-11-24 |
2017-11-14 |
Medimmune Ltd |
Agentes de ligação direcionados contra b7-h1
|
|
WO2011072204A1
(en)
|
2009-12-10 |
2011-06-16 |
Regeneron Pharmaceuticals, Inc. |
Mice that make heavy chain antibodies
|
|
AU2010329934B2
(en)
|
2009-12-10 |
2015-05-14 |
F. Hoffmann-La Roche Ag |
Antibodies binding preferentially human CSF1R extracellular domain 4 and their use
|
|
US10143186B2
(en)
|
2010-02-08 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
|
MX355418B
(es)
|
2010-05-04 |
2018-04-18 |
Five Prime Therapeutics Inc |
Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
|
|
ES2682078T3
(es)
|
2010-06-11 |
2018-09-18 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpo anti-TIM-3
|
|
WO2011159877A2
(en)
|
2010-06-18 |
2011-12-22 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
SG10201504568YA
(en)
|
2010-06-22 |
2015-07-30 |
Regeneron Pharma |
Hybrid light chain mice
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
CN103221428B
(zh)
|
2010-09-09 |
2016-02-10 |
辉瑞公司 |
4-1bb结合分子
|
|
GB201016266D0
(en)
|
2010-09-28 |
2010-11-10 |
Fujifilm Mfg Europe Bv |
Polymers and membranes
|
|
JP6013915B2
(ja)
*
|
2010-11-17 |
2016-10-25 |
中外製薬株式会社 |
血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
EP2714738B1
(en)
*
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
WO2013006490A2
(en)
*
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
US8790651B2
(en)
*
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
CN102492038B
(zh)
|
2011-12-09 |
2014-05-28 |
中国人民解放军军事医学科学院基础医学研究所 |
抗人Tim-3的中和性单克隆抗体L3D及其用途
|
|
US10023643B2
(en)
|
2011-12-15 |
2018-07-17 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R and uses thereof
|
|
EP2812355A4
(en)
|
2012-02-06 |
2016-03-02 |
Hoffmann La Roche |
COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS
|
|
IN2014DN07022A
(enExample)
|
2012-02-21 |
2015-04-10 |
Inst Nat Sante Rech Med |
|
|
JP2015513535A
(ja)
|
2012-02-21 |
2015-05-14 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
ウイルス侵入補助因子としてのｔｉｍレセプター
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
JP2015517490A
(ja)
|
2012-05-11 |
2015-06-22 |
ファイブ プライム セラピューティックス インコーポレイテッド |
コロニー刺激因子１受容体（ｃｓｆ１ｒ）を結合させる抗体を用いて状態を治療する方法
|
|
US9212224B2
(en)
|
2012-05-15 |
2015-12-15 |
Bristol-Myers Squibb Company |
Antibodies that bind PD-L1 and uses thereof
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014022332A1
(en)
|
2012-07-31 |
2014-02-06 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
|
SG10201906328RA
(en)
|
2012-08-31 |
2019-08-27 |
Five Prime Therapeutics Inc |
Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
|
|
EP3424530A1
(en)
*
|
2013-03-15 |
2019-01-09 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
US20150000806A1
(en)
*
|
2013-06-28 |
2015-01-01 |
Octavia A. VILORIO |
Carry bag with attachment accessory
|
|
DE102013215334A1
(de)
|
2013-08-05 |
2015-02-05 |
Tridonic Gmbh & Co Kg |
Dimmbare LED-Leuchtmittelstrecke
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
|
US20150273033A1
(en)
|
2013-11-05 |
2015-10-01 |
Cognate Bioservices, Inc. |
Combinations of checkpoint inhibitors and therapeutics to treat cancer
|
|
CN103721255A
(zh)
|
2014-01-07 |
2014-04-16 |
苏州大学 |
共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
|
|
CN103936853B
(zh)
|
2014-01-26 |
2016-08-17 |
中国人民解放军军事医学科学院基础医学研究所 |
一种检测tim-3试剂盒及其使用方法
|
|
CN104072615B
(zh)
|
2014-01-26 |
2016-08-24 |
中国人民解放军军事医学科学院基础医学研究所 |
一种能阻断Tim-3信号通路的人Tim-3融合蛋白
|
|
DK3099717T3
(da)
|
2014-01-31 |
2019-07-01 |
Novartis Ag |
Antistofmolekyler med tim-3 og anvendelser deraf
|
|
JP2017515841A
(ja)
|
2014-05-13 |
2017-06-15 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
|
|
AU2015266958A1
(en)
|
2014-05-28 |
2016-12-08 |
Agenus Inc. |
Anti-GITR antibodies and methods of use thereof
|
|
JP6449338B2
(ja)
|
2014-06-06 |
2019-01-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
|
|
AU2015287969B2
(en)
|
2014-07-07 |
2020-07-09 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating cancer
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
GB201419094D0
(en)
*
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
CA2965960A1
(en)
|
2014-10-27 |
2016-05-06 |
Agency For Science, Technology And Research |
Anti-tim-3 antibodies
|
|
WO2016070051A2
(en)
|
2014-10-31 |
2016-05-06 |
Oncomed Pharmaceuticals, Inc. |
Combination therapy for treatment of disease
|
|
PL3215532T3
(pl)
*
|
2014-11-06 |
2020-03-31 |
F. Hoffmann-La Roche Ag |
Przeciwciała anty-TIM3 i sposoby ich zastosowania
|
|
LT3221346T
(lt)
|
2014-11-21 |
2020-11-10 |
Bristol-Myers Squibb Company |
Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
CA2974956A1
(en)
|
2015-01-29 |
2016-08-04 |
The Trustees Of The University Of Pennsylvania |
Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
|
|
CN104592388B
(zh)
|
2015-03-02 |
2017-05-31 |
中国人民解放军总医院 |
一种抗人Tim‑3的单克隆抗体的抗原结合部分
|
|
ES2979088T3
(es)
|
2015-03-05 |
2024-09-24 |
Fred Hutchinson Cancer Center |
Proteínas de fusión inmunomoduladoras y usos de las mismas
|
|
JP2018510151A
(ja)
|
2015-03-06 |
2018-04-12 |
ソレント・セラピューティクス・インコーポレイテッド |
Ｔｉｍ３に結合する抗体医薬
|
|
CN107847589B
(zh)
|
2015-04-01 |
2022-03-29 |
安奈普泰斯生物有限公司 |
针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
|
|
WO2016166139A1
(en)
|
2015-04-14 |
2016-10-20 |
Eberhard Karls Universität Tübingen |
Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
|
|
EP3283508B1
(en)
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
SG11201708223QA
(en)
|
2015-04-17 |
2017-11-29 |
Bristol Myers Squibb Co |
Compositions comprising a combination of an anti-pd-1 antibody and another antibody
|
|
US20180298095A1
(en)
|
2015-04-24 |
2018-10-18 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
|
US20180153986A1
(en)
|
2015-04-24 |
2018-06-07 |
The Brigham And Women's Hospital, Inc. |
Interactions between ceacam and tim family members
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
WO2016179472A2
(en)
|
2015-05-07 |
2016-11-10 |
University Of Maryland, Baltimore |
Modulation of natural killer cell tolerance
|
|
EP3316902A1
(en)
|
2015-07-29 |
2018-05-09 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
WO2017031242A1
(en)
|
2015-08-20 |
2017-02-23 |
Sutro Biopharma, Inc. |
Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
|
|
KR101785155B1
(ko)
|
2015-09-22 |
2017-10-16 |
국립암센터 |
Ｔｉｍ－３을 표적으로 하는 뇌손상 질환 치료용 조성물 및 이의 스크리닝 방법
|
|
EP3356821B1
(en)
|
2015-10-02 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
|
SMT202100506T1
(it)
|
2015-10-02 |
2021-11-12 |
Hoffmann La Roche |
Anticorpi bispecifici specifici per pd1 e tim3
|
|
SMT202200118T1
(it)
|
2015-11-03 |
2022-05-12 |
Janssen Biotech Inc |
Anticorpi che legano specificamente pd-1 e loro usi
|
|
PL3443009T3
(pl)
|
2016-04-12 |
2022-01-31 |
Symphogen A/S |
Przeciwciała i kompozycje anty-tim-3
|
|
TWI781934B
(zh)
|
2016-05-27 |
2022-11-01 |
美商艾吉納斯公司 |
抗-tim-3抗體及其使用方法
|
|
JP7027401B2
(ja)
|
2016-07-14 |
2022-03-01 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｉｍ３に対する抗体およびその使用
|
|
JOP20190013A1
(ar)
|
2016-08-25 |
2019-01-31 |
Lilly Co Eli |
أجسام مضادة لـ (تي آي ام -3)
|
|
BR112019003976A2
(pt)
|
2016-08-26 |
2019-05-28 |
Beigene, Ltd. |
anticorpos anti-tim-3 e seu uso
|
|
WO2018058123A1
(en)
|
2016-09-26 |
2018-03-29 |
Advantagene, Inc. |
Methods of treating tim-3 elevation
|
|
BR112019008861A2
(pt)
|
2016-11-01 |
2019-07-09 |
Tesaro, Inc. |
anticorpos direcionados contra imunoglobulina de células t e proteína de mucina 3 (tim-3)
|
|
EP3551659A1
(en)
|
2016-12-08 |
2019-10-16 |
Eli Lilly and Company |
Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
|
|
JOP20190133A1
(ar)
|
2016-12-08 |
2019-06-02 |
Innovent Biologics Suzhou Co Ltd |
أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
|
|
CN106632675A
(zh)
|
2016-12-15 |
2017-05-10 |
常州格露康生物医药科技有限公司 |
一种抗人Tim‑3单克隆抗体8E11及其制备方法
|
|
TWI665216B
(zh)
|
2016-12-29 |
2019-07-11 |
財團法人生物技術開發中心 |
抗人類tim-3抗體及其使用方法
|
|
US11046764B2
(en)
|
2017-01-03 |
2021-06-29 |
Trellis Bioscience, Llc |
Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
|
|
CA3185303A1
(en)
|
2017-04-05 |
2018-10-11 |
Symphogen A/S |
Combination therapies targeting pd-a, tim-3, and lag-3
|
|
JOP20190222A1
(ar)
|
2017-04-11 |
2019-09-24 |
Zymeworks Inc |
الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
|
|
BR112020003362A2
(pt)
|
2017-08-28 |
2020-08-18 |
Bristol-Myers Squibb Company |
antagonistas de tim-3 para o tratamento e diagnóstico de cânceres
|
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
|
KR20250078626A
(ko)
|
2018-01-12 |
2025-06-02 |
브리스톨-마이어스 스큅 컴퍼니 |
Tim3에 대한 항체 및 그의 용도
|
|
US20210363242A1
(en)
|
2018-01-16 |
2021-11-25 |
Bristol-Myers Squibb Company |
Methods of treating cancer with antibodies against tim3
|